TAP taps McKenzie
This article was originally published in The Tan Sheet
Executive Summary
Alan MacKenzie serves as president of Takeda/Abbott Labs joint venture TAP Pharmaceutical Products, effective Sept. 1. Most recently, MacKenzie headed Takeda Pharmaceuticals North America after holding other senior positions, such as president of sales and director of marketing. The exec succeeds Thomas Watkins upon the expiration of his six-year term. After assisting in the transition, Watkins will return to senior management at Abbott, where he previously served as VP-Abbott Health Systems...
You may also be interested in...
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.